Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Single nucleotide polymorphism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Single nucleotide polymorphism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-004323-37 Sponsor Protocol Number: BOS-IIG-01 Start Date*: 2015-03-24
    Sponsor Name:Fundación PETHEMA para el tratamiento de la leucemia y el linfoma
    Full Title: Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
    Medical condition: Patients with chromosome Philadelphia positive (Ph+) in chronic phase mielogenus leukemia (CP CML)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002387-16 Sponsor Protocol Number: SI-C-060 Start Date*: 2015-11-16
    Sponsor Name:Solvotrin Innovations Ltd
    Full Title: The Role of Tetracyclines in the Personalised Management of MMP-9 and Cardiovascular Function in Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001714-96 Sponsor Protocol Number: R2222-RSV-1332 Start Date*: 2015-11-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ...
    Medical condition: Medically attended respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001859-39 Sponsor Protocol Number: TEDY Start Date*: 2013-10-02
    Sponsor Name:Leiden University Medical Center
    Full Title: TElmisartan in the management of abDominal aortic aneurYsm (TEDY)
    Medical condition: Abdominal aortc aneurysm
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10000051 Abdominal aneurysm LLT
    14.1 10047065 - Vascular disorders 10002889 Aortic aneurysms and dissections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004592-35 Sponsor Protocol Number: 6836 Start Date*: 2010-06-16
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-007018-39 Sponsor Protocol Number: Persephone Start Date*: 2007-08-09
    Sponsor Name:Cambridge Hospitals NHS Foundation Trust and Cambridge University
    Full Title: Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve
    Medical condition: HER2 positive early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002793-23 Sponsor Protocol Number: AI444-042 Start Date*: 2012-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4 Revised Protocol Number ...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015502-19 Sponsor Protocol Number: EMR200136_022 Start Date*: 2009-12-14
    Sponsor Name:Merck Serono SA – Geneva
    Full Title: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002437-15 Sponsor Protocol Number: BO42354 Start Date*: 2021-09-23
    Sponsor Name:Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADOLESCENT AND PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
    Medical condition: Atypical Hemolytic Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020219-35 Sponsor Protocol Number: Start Date*: 2011-07-18
    Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust
    Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI
    Medical condition: Cardiovascular disease - Acute coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002331-28 Sponsor Protocol Number: 20190006 Start Date*: 2020-03-10
    Sponsor Name:Amgen Inc.
    Full Title: Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
    Medical condition: Episodic or chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2011-004063-77 Sponsor Protocol Number: ACCEPT Start Date*: 2013-01-17
    Sponsor Name:Klinikum der Universität München, Anstalt des öffentlichen Rechts
    Full Title: Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
    Medical condition: histologically confirmed diagnosis of metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004072-30 Sponsor Protocol Number: GETNE-1408 Start Date*: 2015-01-22
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) pr...
    Medical condition: Patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumours (pNET).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000245-20 Sponsor Protocol Number: FSJD-RAL-2010 Start Date*: 2011-06-21
    Sponsor Name:FUNDACIÓ SANT JOAN DE DEU
    Full Title: ENSAYO CLÍNICO DOBLE CIEGO A SEIS MESES, CONTROLADO CON PLACEBO, DE LA EFICACIA DE RALOXIFENO COMO TRATAMIENTO ADYUVANTE DE LOS SÍNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA, EN MUJERES POSTMENOPÁUSICAS ...
    Medical condition: SINTOMAS NEGATIVOS EN ESQUIZOFRENIA
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001027-20 Sponsor Protocol Number: CACZ885GDE01T Start Date*: 2012-04-03
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.
    Medical condition: adult onset Still's disease (AOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042061 Still's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023740-32 Sponsor Protocol Number: 2010-023740-32 Start Date*: 2011-05-18
    Sponsor Name:Haukeland University Hospital [...]
    1. Haukeland University Hospital
    2.
    Full Title: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder
    Medical condition: The goal of this work is to identify genes associated with good response of bipolar patients to two commonly used mood stabilizing agents, lithium and valproate. 1. All patients will be started on ...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10004908 Bipolar affective disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015556-15 Sponsor Protocol Number: 101MS325 Start Date*: 2010-05-07
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) HU (Prematurely Ended) NL (Prematurely Ended) SI (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001508-31 Sponsor Protocol Number: R1500-CL-1643 Start Date*: 2017-11-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally T...
    Medical condition: Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) NO (Completed) SE (Completed) DK (Completed) PL (Completed) AT (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-005531-13 Sponsor Protocol Number: MED3-201401 Start Date*: 2015-11-26
    Sponsor Name:Univerity of Bonn
    Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ...
    Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000368-90 Sponsor Protocol Number: 218MS205 Start Date*: 2012-08-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 15:45:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA